The VBP101 trial, a Phase 1/2a study of trem-cel (VOR33) in combination with Mylotarg™, is actively enrolling patients. This clinical trial will evaluate trem-cel in patients with AML undergoing an allogeneic hematopoietic cell transplant (HCT).
The FDA has cleared our Investigational New Drug (IND) application for VCAR33ALLO, a CAR-T cell therapy derived from allogeneic healthy donors that targets CD33. VCAR33ALLO is being studied in the VBP301 clinical trial, which focuses on patients who have relapsed following allogeneic stem cell transplant, including patients who have previously received trem‑cel.
If you have questions, please contact us.
We are applying proven technologies in new ways by genetically modifying healthy donor HSCs for protection and enabling use of modalities such as ADCs and CAR-Ts post-transplant.
